Cell Coast 2024 Presentations

SESSION 1: CELLULAR THERAPIES IN HEMATOLOGIC MALIGNANCIES

Updates on Approved CAR-T for Lymphoma
Julio Chavez, MD - Moffitt Cancer Center

CAR-T for ALL
Bijal Shah, MD - Moffitt Cancer Center

CAR-T Strategies for Multiple Myeloma
Krina Patel, MD - UT MD Anderson Cancer Center

Bi-specifics for Myeloma
Omar Castaneda-Puglianini, MD - Moffitt Cancer Center

Cellular Therapies for Myeloid Malignancies
David Sallman, MD - Moffitt Cancer Center

SESSION 2: CELLULAR THERAPIES IN SOLID TUMOR MALIGNANCIES

Melanoma TILS
Amod Sarnaik, MD - Moffitt Cancer Center

Surgical Considerations for TIL Procurement
John Mullinax, MD - Moffitt Cancer Center

Novel Cell Therapies for Thoracic Malignancies
Benjamin Creelan, MD - Moffitt Cancer Center

Afami-cel TCR for Sarcoma
Brian Van Tine, MD, PhD - Washington University

Intravesical TIL for Bladder Cancer
Michael Poch, MD - Moffitt Cancer Center

SESSION 3: THE REAL WORLD AND THE FUTURE WORLD FOR CELL THERAPY

Point of Care CAR T Manufacturing
Natasha Kekre, BSc, MD, MPH, FRCPC - University of Ottawa

Real World CAR-T for Multiple Myeloma
Doris Hansen, MD - Moffitt Cancer Center

Infections Occurring in our ICE T Patient Population
Aliyah Baluch, MD - Moffitt Cancer Center

CAR-T in Autoimmune Diseases
Sayeef Mirza, MD, MPH - Moffitt Cancer Center

NK Cellular Therapies
Rizwan Romee, MD - Dana Farber Cancer Institute

Future of TILs
Allison Betof Warner, MD, PhD - Stanford Medicine

SESSION 4: OPERATIONAL READINESS IN THE COMMUNITY, CELL THERAPY CENTER, AND BEYOND

Interface of Community Oncologists & Academic Centers for Cellular Therapies
Lilit Karapetyan, MD, MS - Moffitt Cancer Center
Mihaela Druta, MD - Moffitt Cancer Center
Ciara Freeman, MD, PhD - Moffitt Cancer Center
Shivtaj Mann, DO – Florida Cancer Specialists

Business Operations of Cellular Therapies
Leigh Jansen, MD - McKinsey & Company